|Challenge title||bloodstream infection testing|
|Form of partnership||Chinese company looking for technology partners|
Life Science & Healthcare
|Challenge description||Challenge background:
Bloodstream infection (BSI) can be caused by pathogens such as bacteria, fungi or viruses and is a common complication for hospitalized patients. When BSI develops into life-threatening organ function impairment, it is termed sepsis. The incidence of bloodstream infection (BSI) is increasing year by year in the world. Early identification and diagnosis of BSI are of great significance for clinical treatment. The currently accepted “gold standard” for diagnosing BSI is the blood culture method, which identifies the pathogen by biochemical or mass spectrometry methods. Traditional diagnostic methods are accurate and reliable, but exist great limitations, such as long culture cycle (generally 4 to 11 days), low sensitivity to slow growth, intracellular growth and microorganisms that are difficult to culture, and false negatives frequently.
We are looking for companies with knowledge of the following requirements:
It is a rapid detection method that is based on real-time PCR method by using whole blood as samples.
Indicators of requirement: